| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 6, 2025 | Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” o... |
| May 23, 2025 | IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules | $3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical... |
| Apr 25, 2025 | Better Choice Company Announces Closing of the SRx Health Merger, Name/Symbol Change and Completes $8.8 Million Private Placement Priced Above Last Market Closing Price | TAMPA, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced the closing of its business combination with SRx Health... |
| Apr 11, 2025 | Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase ... |
| Apr 4, 2025 | AMERICAN REBEL ANNOUNCES UP TO $11 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES | $2.5 million upfront with up to approximately $8.5 million of potential aggregate gross proceeds upon the exercise in full of warrants
Nashville, TN, April 04, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) (“American... |
| Mar 21, 2025 | PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules | NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, today announced that it has entered into a definitive agreement with several investors for... |
| Mar 21, 2025 | PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules | NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, today announced that it has entered into a definitive agreement with several investors for... |
| Mar 13, 2025 | Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | Proceeds from today’s financing, when added to existing cash, fund operations through Q1 2026
The Company is planning to announce interim data from its ongoing Halneuron® Phase 2b chemotherapy induced neuropathic pain (“CINP”) trial in Q4 2... |
| Mar 7, 2025 | Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules | NEW YORK and MELBOURNE, Australia, March 07, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced ... |
| Mar 3, 2025 | Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules | BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, today annou... |
| Mar 3, 2025 | Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules | BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, today annou... |
| Feb 27, 2025 | PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, to... |
| Feb 27, 2025 | SUNation Energy Announces $20 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules | RONKONKOMA, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- SUNation Energy, Inc. (Nasdaq: SUNE), a leading provider of sustainable solar energy and backup power solutions for households, businesses, and municipalities, today announced that it has ... |
| Feb 13, 2025 | Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insiders
Capital raise to fund Edesa’s CXCL10 antibody program through the end of fiscal 2026
TORONTO, Feb. 13, 2025 (GLO... |
| Feb 13, 2025 | LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | PASADENA, CALIF., Feb. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced the closing of its previously announced reg... |
| Feb 6, 2025 | 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | WASHINGTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its p... |
| Feb 5, 2025 | CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell thera... |
| Feb 5, 2025 | 60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | WASHINGTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered ... |
| Jan 31, 2025 | SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market | DENVER, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced it has entered into a securities purchase agreement with a single institutional investor for the issuance and sale... |
| Jan 31, 2025 | SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market | DENVER, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced it has entered into a securities purchase agreement with a single institutional investor for the issuance and sale... |
| Jan 30, 2025 | Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today ... |
| Jan 30, 2025 | Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today ... |
| Jan 29, 2025 | 60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | WASHINGTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered ... |
| Jan 29, 2025 | 60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | WASHINGTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered ... |
| Jan 28, 2025 | SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cance... |
| Jan 27, 2025 | Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with imp... |
| Jan 15, 2025 | Mercurity Fintech Holding Inc. Priced Additional $8 Million Private Placement Financing to Strengthen Its Business Development in AI Manufacturing Innovations | New York, NY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Mercurity Fintech Holding Inc. (the “Company,” “we,” “us,” “our company,” or “MFH”) (Nasdaq: MFH), a digital fintech group, is pleased to announce the pricing of another private investment in ... |
| Jan 15, 2025 | Mercurity Fintech Holding Inc. Priced Additional $8 Million Private Placement Financing to Strengthen Its Business Development in AI Manufacturing Innovations | New York, NY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Mercurity Fintech Holding Inc. (the “Company,” “we,” “us,” “our company,” or “MFH”) (Nasdaq: MFH), a digital fintech group, is pleased to announce the pricing of another private investment in ... |
| Jan 13, 2025 | Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules | NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it ha... |
| Jan 8, 2025 | Lifeward Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabi... |
| Jan 8, 2025 | Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules | HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase ... |
| Jan 6, 2025 | Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules | SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an ag... |
| Jan 6, 2025 | Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules | HINGHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 4,000,002 shares of the Company’s common stock at a purchase ... |
| Jan 3, 2025 | Expion360 Inc. Announces Closing of $2.6 Million Registered Direct Offering and Private Placement Priced at the Market Under Nasdaq Rules | REDMOND, Ore., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Expion360 Inc. (Nasdaq: XPON) (the “Company”), an industry leader in lithium-ion battery power storage solutions, today announced the closing of its previously announced registered direct off... |
| Jan 3, 2025 | Alset Inc. Announces Closing of $1.5 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules | BETHESDA, MD, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Alset Inc. (NASDAQ: AEI) (the “Company”), a diversified company engaged through its subsidiaries in the development of EHome communities and real estate, financial services, digital transforma... |
| Jan 3, 2025 | Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules | SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 ... |
| Jan 3, 2025 | Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules | SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 ... |
| Jan 3, 2025 | Expion360 Inc. Announces Closing of $2.6 Million Registered Direct Offering and Private Placement Priced at the Market Under Nasdaq Rules | REDMOND, Ore., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Expion360 Inc. (Nasdaq: XPON) (the “Company”), an industry leader in lithium-ion battery power storage solutions, today announced the closing of its previously announced registered direct off... |
| Jan 3, 2025 | Alset Inc. Announces Closing of $1.5 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules | BETHESDA, MD, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Alset Inc. (NASDAQ: AEI) (the “Company”), a diversified company engaged through its subsidiaries in the development of EHome communities and real estate, financial services, digital transforma... |
| Jan 2, 2025 | Expion360 Inc. Announces $2.6 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules | REDMOND, Ore., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Expion360 Inc. (Nasdaq: XPON) (the “Company”), an industry leader in lithium-ion battery power storage solutions, today announced that it has entered into definitive agreements with instituti... |
| Jan 2, 2025 | Alset Inc. Announces $1.5 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules | BETHESDA, MD, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Alset Inc. (NASDAQ: AEI) (the “Company”), a diversified company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital tran... |
| Dec 30, 2024 | Gaxos.ai Inc. Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Gaxos.ai Inc. raises approximately $9 million in gross proceeds in December 2024
Roseland, NJ, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (Nasdaq: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applicat... |
| Dec 27, 2024 | Gaxos.ai Inc. Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Roseland, NJ, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (Nasdaq: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that it has entered into definitive ... |
| Dec 27, 2024 | Gaxos.ai Inc. Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Roseland, NJ, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (Nasdaq: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that it has entered into definitive ... |
| Dec 23, 2024 | Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effecti... |
| Dec 20, 2024 | Gaxos.ai Inc. Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Roseland, NJ, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (Nasdaq: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced the closing of its previously announ... |
| Dec 20, 2024 | Gaxos.ai Inc. Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Roseland, NJ, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (Nasdaq: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced the closing of its previously announ... |
| Dec 19, 2024 | Gaxos.ai Inc. Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Roseland, NJ, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (Nasdaq: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that it has entered into definitive ... |
| Dec 16, 2024 | SEALSQ Announces Pricing of $25.0 Million Registered Direct Offering Priced Above Market Under NASDAQ Rules | Geneva, Switzerland , Dec. 16, 2024 (GLOBE NEWSWIRE) --
SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and so... |
| Dec 13, 2024 | Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules | Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammator... |
| Dec 12, 2024 | SEALSQ Announces Pricing of $10.0 Million Registered Direct Offering Priced Above Market Under NASDAQ Rules | Geneva, Switzerland, Dec. 12, 2024 (GLOBE NEWSWIRE) --
SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and sof... |
| Dec 12, 2024 | Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules | Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammator... |
| Dec 12, 2024 | Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules | BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced... |
| Dec 12, 2024 | POET Technologies Announces US$25 Million Offering Priced at a Premium to Market | TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. ("POET" or the "Corporation") (TSXV: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) a... |
| Nov 18, 2024 | HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules | MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen h... |
| Nov 18, 2024 | Swvl Announces Pricing of $4.7 Million Private Placement Priced At-the-Market Under Nasdaq Rules to Accelerate Expansion in High Value Markets | DUBAI, United Arab Emirates, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Swvl Holdings Corp ("Swvl" or the "Company") (Nasdaq: SWVL), a leading provider of technology-driven mobility solutions for enterprises and governments, toda... |
| Nov 18, 2024 | Swvl Announces Pricing of $4.7 Million Private Placement Priced At-the-Market Under Nasdaq Rules to Accelerate Expansion in High Value Markets | DUBAI, United Arab Emirates, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Swvl Holdings Corp ("Swvl" or the "Company") (Nasdaq: SWVL), a leading provider of technology-driven mobility solutions for enterprises and governments, toda... |
| Nov 8, 2024 | Stryve Foods, Inc. Announces Pricing of $2.9 Million Public Offering Priced At-Market According to Nasdaq Rules | PLANO, Texas, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snacking platform and leader in the air-dried meat snack industry in the United States, today announced the p... |
| Nov 8, 2024 | Stryve Foods, Inc. Announces Pricing of $2.9 Million Public Offering Priced At-Market According to Nasdaq Rules | PLANO, Texas, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snacking platform and leader in the air-dried meat snack industry in the United States, today announced the p... |
| Nov 6, 2024 | Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules | PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announc... |
| Oct 31, 2024 | Bionano Announces $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules | SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 9,881,113 s... |
| Oct 31, 2024 | Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules | SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq rules for the purchase and sale of an ag... |
| Oct 29, 2024 | Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 ... |
| Oct 29, 2024 | Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes... |
| Oct 10, 2024 | Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio... |
| Oct 10, 2024 | Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio... |
| Oct 2, 2024 | Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules | IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Ag... |
| Sep 30, 2024 | Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules | SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mit... |
| Sep 27, 2024 | Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules | – Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 –
– Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million i... |
| Sep 27, 2024 | Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules | – Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 –
– Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million i... |
| Sep 26, 2024 | Banzai Announces Closing of $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules | SEATTLE, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced the closing of ... |
| Sep 26, 2024 | Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules | MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of... |
| Sep 24, 2024 | Banzai Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules | SEATTLE, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that it has ent... |
| Sep 19, 2024 | Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effecti... |
| Sep 9, 2024 | BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules | SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the closing of its u... |
| Sep 9, 2024 | AmpliTech Group Announces Pricing of $1.0 Million Registered Direct Offering, Priced At-The-Market | HAUPPAUGE, N.Y., Sept. 09, 2024 (GLOBE NEWSWIRE) -- AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW) (the “Company”), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, ... |
| Sep 6, 2024 | 60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules | WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closin... |
| Sep 6, 2024 | 60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules | WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closin... |
| Sep 4, 2024 | 60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules | WASHINGTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it ha... |
| Aug 30, 2024 | Airship AI Announces Pricing of $8.0 Million Public Offering Priced At-Market According to Nasdaq Rules | REDMOND, Wash., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, today announced the pricing of a pu... |
| Aug 30, 2024 | BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules | SUNNYVALE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the pricing of its up... |
| Aug 30, 2024 | BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules | SUNNYVALE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the pricing of its up... |
| Aug 29, 2024 | Airship AI Announces Pricing of $8.0 Million Public Offering Priced At-Market According to Nasdaq Rules | REDMOND, Wash., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, today announced the pricing of a pu... |
| Aug 23, 2024 | Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | MINNEAPOLIS, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered in... |
| Aug 21, 2024 | Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules | CUPERTINO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the ... |
| Aug 8, 2024 | XWELL Announces Closing of $1.4 Million Registered Direct Offering Priced At Premium to Market | NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced the closing of its previously announced registered direct offering p... |
| Aug 8, 2024 | XWELL Announces Closing of $1.4 Million Registered Direct Offering Priced At Premium to Market | NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced the closing of its previously announced registered direct offering p... |
| Aug 6, 2024 | XWELL Announces $1.4 Million Registered Direct Offering Priced At Premium to Market | NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced that it has entered into definitive agreements for the issuance and ... |
| Aug 5, 2024 | LogicMark, Inc. Announces Closing of $4.5 Million Public Offering Priced At-The-Market | LOUISVILLE, Ky., Aug. 05, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems, health communications devices, and technology for the growing care economy, today announced the closing of... |
| Aug 5, 2024 | LogicMark, Inc. Announces Closing of $4.5 Million Public Offering Priced At-The-Market | LOUISVILLE, Ky., Aug. 05, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems, health communications devices, and technology for the growing care economy, today announced the closing of... |
| Aug 2, 2024 | LogicMark, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market | LOUISVILLE, Ky., Aug. 02, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems, health communications devices, and technology for the growing care economy, today announced the pricing of... |
| Aug 2, 2024 | LogicMark, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market | Special Stockholder Meeting Also Announced to be Held on October 1, 2024
LOUISVILLE, Ky., Aug. 02, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems, health communications devices, an... |
| Aug 1, 2024 | Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules | PITTSBURGH, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it ... |
| Aug 1, 2024 | Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules | PITTSBURGH, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced tha... |
| Jul 31, 2024 | SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market | NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of canc... |
| Jul 31, 2024 | IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules | LAWRENCEVILLE, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that it has entered into definitive securities purch... |
| Jul 26, 2024 | Motorsport Games Announces $1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or the “Company”), today announced that it has entered into definitive agreements for the sale and issuance of 460,830 shares of Class A commo... |
| Jul 26, 2024 | Motorsport Games Announces $1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or the “Company”), today announced that it has entered into definitive agreements for the sale and issuance of 460,830 shares of Class A commo... |
| Jul 24, 2024 | Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules | MINNEAPOLIS, July 24, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered in... |
